Neuphoria Therapeutics (NEUP) Competitors

Neuphoria Therapeutics logo
$2.28 +0.01 (+0.48%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NEUP vs. GOSS, XBIT, KLRS, ONCY, and CRBP

Should you buy Neuphoria Therapeutics stock or one of its competitors? Neuphoria Therapeutics's main competitors and comparable companies include Gossamer Bio (GOSS), XBiotech (XBIT), Kalaris Therapeutics (KLRS), Oncolytics Biotech (ONCY), and Corbus Pharmaceuticals (CRBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neuphoria Therapeutics compare to Gossamer Bio?

Neuphoria Therapeutics (NASDAQ:NEUP) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 1.6% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Neuphoria Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$1.17M10.50-$13.45M-$6.22N/A
Gossamer Bio$48.47M1.39-$170.37M-$46.56N/A

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 208.37%. Gossamer Bio has a consensus target price of $246.40, indicating a potential upside of 2,131.88%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Neuphoria Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30

Neuphoria Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -159.49%. Gossamer Bio's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -38.31% -28.92%
Gossamer Bio -159.49%N/A -112.10%

Neuphoria Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market.

In the previous week, Gossamer Bio had 19 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 20 mentions for Gossamer Bio and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.26 beat Gossamer Bio's score of 0.16 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gossamer Bio
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Gossamer Bio beats Neuphoria Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Neuphoria Therapeutics has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A-$45.54M-$1.43N/A
Neuphoria Therapeutics$1.17M10.50-$13.45M-$6.22N/A

XBiotech's return on equity of -33.03% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -33.03% -31.57%
Neuphoria Therapeutics N/A -38.31%-28.92%

XBiotech has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

In the previous week, XBiotech and XBiotech both had 1 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.26 beat XBiotech's score of -0.61 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
XBiotech Negative
Neuphoria Therapeutics Neutral

Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 208.37%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

55.7% of XBiotech shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 21.1% of XBiotech shares are held by company insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Neuphoria Therapeutics beats XBiotech on 7 of the 11 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Kalaris Therapeutics and 1 mentions for Neuphoria Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.60 beat Neuphoria Therapeutics' score of 0.26 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kalaris Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neuphoria Therapeutics' return on equity of -38.31% beat Kalaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kalaris TherapeuticsN/A -68.76% -41.32%
Neuphoria Therapeutics N/A -38.31%-28.92%

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kalaris Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 1,211.19%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 208.37%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kalaris Therapeutics is more favorable than Neuphoria Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Neuphoria Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kalaris TherapeuticsN/AN/A-$43.44M-$1.84N/A
Neuphoria Therapeutics$1.17M10.50-$13.45M-$6.22N/A

Kalaris Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Summary

Kalaris Therapeutics beats Neuphoria Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Oncolytics Biotech's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A N/A -477.70%
Neuphoria Therapeutics N/A -38.31%-28.92%

Oncolytics Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 1,207.19%. Neuphoria Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 208.37%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Neuphoria Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Oncolytics Biotech had 5 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 6 mentions for Oncolytics Biotech and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.26 beat Oncolytics Biotech's score of -0.19 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncolytics Biotech
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncolytics Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 4.7% of Oncolytics Biotech shares are owned by insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Neuphoria Therapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-$28.76M-$0.32N/A
Neuphoria Therapeutics$1.17M10.50-$13.45M-$6.22N/A

Summary

Oncolytics Biotech beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Corbus Pharmaceuticals has a beta of 2.8, suggesting that its share price is 180% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corbus PharmaceuticalsN/AN/A-$78.54M-$6.10N/A
Neuphoria Therapeutics$1.17M10.50-$13.45M-$6.22N/A

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neuphoria Therapeutics' return on equity of -38.31% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corbus PharmaceuticalsN/A -100.96% -82.70%
Neuphoria Therapeutics N/A -38.31%-28.92%

Corbus Pharmaceuticals currently has a consensus price target of $35.67, indicating a potential upside of 1,084.94%. Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 208.37%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Neuphoria Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Corbus Pharmaceuticals had 17 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 18 mentions for Corbus Pharmaceuticals and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.26 beat Corbus Pharmaceuticals' score of 0.10 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corbus Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Corbus Pharmaceuticals beats Neuphoria Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NEUP vs. The Competition

MetricNeuphoria TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$12.39M$3.98B$7.60B$11.73B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-0.3724.6233.6629.94
Price / Sales10.5915.428.305.63
Price / CashN/A22.9521.0121.90
Price / Book0.504.164.443.72
Net Income-$13.45M-$24.10M$3.51B$393.84M
7 Day Performance-15.50%-8.45%-6.49%-6.02%
1 Month Performance-30.61%-6.55%-4.89%-7.35%
1 Year Performance-51.69%-6.71%-1.65%-7.46%

Neuphoria Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEUP
Neuphoria Therapeutics
1.7684 of 5 stars
$2.29
+0.9%
$7.00
+205.7%
-51.7%$12.39M$1.17MN/A1
GOSS
Gossamer Bio
2.9879 of 5 stars
$9.77
+3.7%
$256.00
+2,520.3%
-95.4%$59.70M$48.47MN/A162
XBIT
XBiotech
1.0219 of 5 stars
$1.89
+1.1%
N/A-27.9%$57.62MN/AN/A87
KLRS
Kalaris Therapeutics
2.5919 of 5 stars
$2.42
+2.5%
$18.75
+674.8%
-73.6%$57.61MN/AN/A20
ONCY
Oncolytics Biotech
1.7167 of 5 stars
$0.44
-2.1%
$5.00
+1,037.9%
-63.6%$57.61MN/AN/A29

Related Companies and Tools


This page (NASDAQ:NEUP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners